Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study
To estimate inappropriate dosing of dipeptidyl peptidase-4 (DPP-4) inhibitors and to assess the risk of emergency department visits, hypoglycemia, and mortality in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) prescribed inappropriate DPP-4 inhibitor doses because limited real-world information is available regarding rates of DPP-4 inhibitor dose adjustment and its safety in patients with T2DM and CKD.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Sangmo Hong, Kyungdo Han, Cheol-Young Park Tags: Original article Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Emergency Medicine | Endocrinology | Internal Medicine | Study | Urology & Nephrology